BR112013025782A2 - métodos de monitoramento e análise de diagnósticos de perfis de atividade metabólica e usos terapêuticos dos mesmos - Google Patents

métodos de monitoramento e análise de diagnósticos de perfis de atividade metabólica e usos terapêuticos dos mesmos

Info

Publication number
BR112013025782A2
BR112013025782A2 BR112013025782A BR112013025782A BR112013025782A2 BR 112013025782 A2 BR112013025782 A2 BR 112013025782A2 BR 112013025782 A BR112013025782 A BR 112013025782A BR 112013025782 A BR112013025782 A BR 112013025782A BR 112013025782 A2 BR112013025782 A2 BR 112013025782A2
Authority
BR
Brazil
Prior art keywords
diagnostics
analyzing
monitoring
methods
metabolic activity
Prior art date
Application number
BR112013025782A
Other languages
English (en)
Other versions
BR112013025782B1 (pt
Inventor
Fernando Patolsky
Hagit Pretz-Soroka
Reuven Tirosh
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Publication of BR112013025782A2 publication Critical patent/BR112013025782A2/pt
Publication of BR112013025782B1 publication Critical patent/BR112013025782B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

abstract not avaible
BR112013025782-2A 2011-04-06 2012-04-04 Método de medição de uma atividade metabólica (am) de uma célula, método ex-vivo de diagnóstico de uma doença associada a uma atividade metabólica modificada em um indivíduo em necessidade respectiva, método ex-vivo de otimização do tratamento de uma doença, método ex- vivo de monitoramento do tratamento de uma doença em um indivíduo e método ex-vivo de identificação de um agente capaz de alterar uma atividade metabólica das células BR112013025782B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US61/472,213 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (2)

Publication Number Publication Date
BR112013025782A2 true BR112013025782A2 (pt) 2016-12-20
BR112013025782B1 BR112013025782B1 (pt) 2022-09-06

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013025782-2A BR112013025782B1 (pt) 2011-04-06 2012-04-04 Método de medição de uma atividade metabólica (am) de uma célula, método ex-vivo de diagnóstico de uma doença associada a uma atividade metabólica modificada em um indivíduo em necessidade respectiva, método ex-vivo de otimização do tratamento de uma doença, método ex- vivo de monitoramento do tratamento de uma doença em um indivíduo e método ex-vivo de identificação de um agente capaz de alterar uma atividade metabólica das células

Country Status (11)

Country Link
US (3) US8728758B2 (pt)
EP (1) EP2694962B1 (pt)
JP (1) JP5990254B2 (pt)
KR (1) KR102010600B1 (pt)
CN (1) CN103518133B (pt)
AU (1) AU2012240953B2 (pt)
BR (1) BR112013025782B1 (pt)
CA (1) CA2832031C (pt)
DK (1) DK2694962T3 (pt)
ES (1) ES2627154T3 (pt)
WO (1) WO2012137207A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8728758B2 (en) 2011-04-06 2014-05-20 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2015057713A1 (en) * 2013-10-14 2015-04-23 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
JP6609247B2 (ja) 2013-10-22 2019-11-20 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 検知のための方法及びシステム
ITRM20130700A1 (it) 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
EP3387420B1 (en) 2015-12-09 2023-11-15 Ramot at Tel-Aviv University Ltd. Sensing system comprising a nanostructure transistor and corresponding sensing method
US11906463B2 (en) 2016-08-22 2024-02-20 Ramot At Tel-Aviv University Ltd. Methods and systems for detecting bioanalytes
BR112020003485A2 (pt) 2017-08-21 2020-08-25 Savicell Diagnostic Ltd métodos de diagnóstico e de tratamento de câncer de pulmão e de monitoramento de tratamento, e, kit
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
WO2023023114A1 (en) * 2021-08-17 2023-02-23 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1423501A4 (en) * 2001-08-06 2008-08-06 Univ Vanderbilt DEVICE AND METHOD FOR MEASURING THE RESPONSE OF AT LEAST ONE CELL TO A MEDIUM
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
US20090170091A1 (en) * 2006-01-17 2009-07-02 Kenneth Giuliano Method For Predicting Biological Systems Responses
JP5107943B2 (ja) 2006-03-06 2012-12-26 ゼティク テクノロジーズ リミテッド 細胞の表現型を特定するための方法および組成物
WO2011000572A1 (de) * 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
WO2011031803A1 (en) * 2009-09-08 2011-03-17 Nodality, Inc. Analysis of cell networks
US8728758B2 (en) 2011-04-06 2014-05-20 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Also Published As

Publication number Publication date
AU2012240953B2 (en) 2017-02-23
CN103518133B (zh) 2016-08-17
BR112013025782B1 (pt) 2022-09-06
EP2694962A1 (en) 2014-02-12
EP2694962B1 (en) 2017-03-01
US8728758B2 (en) 2014-05-20
DK2694962T3 (en) 2017-06-12
WO2012137207A1 (en) 2012-10-11
CA2832031A1 (en) 2012-10-11
JP5990254B2 (ja) 2016-09-07
KR20140024871A (ko) 2014-03-03
AU2012240953A1 (en) 2013-10-17
US20130224789A1 (en) 2013-08-29
US20180038849A1 (en) 2018-02-08
ES2627154T3 (es) 2017-07-26
JP2014512006A (ja) 2014-05-19
CA2832031C (en) 2019-09-17
KR102010600B1 (ko) 2019-08-13
US9784731B2 (en) 2017-10-10
US20140255972A1 (en) 2014-09-11
CN103518133A (zh) 2014-01-15

Similar Documents

Publication Publication Date Title
BR112013025782A2 (pt) métodos de monitoramento e análise de diagnósticos de perfis de atividade metabólica e usos terapêuticos dos mesmos
BR112014027450A2 (pt) aparelho e métodos de análise microbiológica
BR112015010680A2 (pt) aparelho de sonda ultrassônica, e método de controle de um aparelho de sonda ultrassônica
HK1209995A1 (en) Quantification and analysis of angiography and perfusion
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
EP2680923A4 (en) TISSUE TREATMENT AND MONITORING THROUGH THE USE OF ENERGY
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
BR112015001048A2 (pt) métodos, dispositivo e sistema para a medição de uma pluralidade de parâmetros de coagulação de uma amostra de sangue
FI20126186A (fi) Järjestely ja menetelmä elektrodimittausten suorittamiseksi
DK2663229T3 (da) Bi-hemisfærisk hjernebølgesystem og fremgangsmåde til at udføre bi-hemisfærisk hjernebølgemålinger
BR112014020761A2 (pt) Aparelho médico e método
BR112014000329A2 (pt) método de análise de distúrbios cardiovasculares e uso do mesmo
EP2874647A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
BR112014014213A2 (pt) agentes hemostáticos e método de utilização
FI20115053A0 (fi) Menetelmä ja järjestelmä kardiovaskulaaristen sykeaaltojen visualisoimiseksi
EP2726876A4 (en) METHOD FOR DETERMINING AN ACTIVE CONCENTRATION THROUGH CALIBRATION-FREE ANALYSIS
DK2771696T3 (da) Fremgangsmåder med anvendelse af metabolitpaneler til diagnosticering og differentiering af neonatal encefalopati
BR112015002563A2 (pt) dispositivo e método de monitoramento doméstico de parâmetros hematológicos de pacientes
FR2977489B1 (fr) Procedes de traitement cosmetique et kit
BR112014025507A2 (pt) formulação vesicular e método de tratamento
BR112013030991A2 (pt) uso de gdc-0980 e método de tratamento de mesotelioma
FR2976081B1 (fr) Methode de diagnostic de la tuberculose active
SMT201700103B (it) Bersaglio terapeutico e diagnostico
EP2859898A4 (en) THERAPEUTIC AGENT, METHOD OF TREATMENT AND TESTING METHOD FOR DISEASES ASSOCIATED WITH ACTIVATION OF NEUTROPHILIC GRANULOCYTES
FR2995777B1 (fr) Methode de caracterisation des volumes de la peau

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: CONFORME RESOLUCAO 113/2013, O DEPOSITANTE DEVERA COMPLEMENTAR A RETRIBUICAO DA 7A ANUIDADE, DE ACORDO COM TABELA VIGENTE, REFERENTE A GUIA DE RECOLHIMENTO 29409161803340265.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.